1. Home
  2. SES vs ALT Comparison

SES vs ALT Comparison

Compare SES & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SES
  • ALT
  • Stock Information
  • Founded
  • SES 2012
  • ALT 1997
  • Country
  • SES United States
  • ALT United States
  • Employees
  • SES N/A
  • ALT N/A
  • Industry
  • SES Auto Parts:O.E.M.
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • SES Consumer Discretionary
  • ALT Health Care
  • Exchange
  • SES Nasdaq
  • ALT Nasdaq
  • Market Cap
  • SES 384.0M
  • ALT 292.0M
  • IPO Year
  • SES N/A
  • ALT N/A
  • Fundamental
  • Price
  • SES $1.12
  • ALT $3.83
  • Analyst Decision
  • SES Hold
  • ALT Strong Buy
  • Analyst Count
  • SES 3
  • ALT 6
  • Target Price
  • SES $1.50
  • ALT $17.40
  • AVG Volume (30 Days)
  • SES 5.6M
  • ALT 3.0M
  • Earning Date
  • SES 10-30-2025
  • ALT 08-12-2025
  • Dividend Yield
  • SES N/A
  • ALT N/A
  • EPS Growth
  • SES N/A
  • ALT N/A
  • EPS
  • SES N/A
  • ALT N/A
  • Revenue
  • SES $11,360,000.00
  • ALT $20,000.00
  • Revenue This Year
  • SES $883.92
  • ALT N/A
  • Revenue Next Year
  • SES $159.98
  • ALT $761,880.20
  • P/E Ratio
  • SES N/A
  • ALT N/A
  • Revenue Growth
  • SES N/A
  • ALT N/A
  • 52 Week Low
  • SES $0.20
  • ALT $2.90
  • 52 Week High
  • SES $2.53
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • SES 51.03
  • ALT 51.79
  • Support Level
  • SES $1.09
  • ALT $3.35
  • Resistance Level
  • SES $1.22
  • ALT $3.66
  • Average True Range (ATR)
  • SES 0.07
  • ALT 0.19
  • MACD
  • SES -0.00
  • ALT 0.07
  • Stochastic Oscillator
  • SES 55.32
  • ALT 86.18

About SES SES AI Corporation

SES AI Corp is a developer and manufacturer of high-performance, AI-enhanced Lithium-Metal (Li-Metal) and Lithium-ion (Li-ion) rechargeable battery technologies for electric vehicles (EVs), Urban Air Mobility (UAM), drones, robotics, Battery Energy Storage Systems (BESS) and other applications. It includes Software and Hardware products that are EV, UAM, Drone, Molecular Universe, and Avatar.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: